



Angiotensin-Converting Enzyme in Health and Diseases

Guest Editor:

Dr. Sergei M. Danilov

Department of Medicine,
University of Illinois at Chicago,
Chicago, IL, USA

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Angiotensin I-converting enzyme (ACE) is a Zn²⁺ carboxydipeptidase that plays crucial roles in blood pressure regulation and the development of vascular pathology. Numerous studies have identified ACE as a potent pro-inflammatory modulator that contributes to the recruitment of inflammatory cells into tissues by regulating chemokines and adhesion molecules. Furthermore, ACE not only functions as a cell membrane ectopeptidase but can also be secreted into the extracellular environment by activated myelomonocytic or other lineage cells, acting as a local and systemic regulator of peptides. Given its broad substrate specificity and wide tissue distribution, ACE impacts various biological processes. The well-established association of ACE with immunoinflammatory diseases presents an excellent opportunity for authors and investigators to contribute their original research or review articles to this Special Issue, entitled “Angiotensin-Converting Enzyme in Health and Diseases”. We cordially invite you to share your expertise in ACE function research in this exceptional forum.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)